Completed PHASE2 INTERVENTIONAL 3-arm NCT00291668

Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease

A Phase II, Multi-center, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Assess the Safety and Efficacy of CDP870/Certolizumab Pegol, Dosed Subcutaneously in Patients With Active Crohn's Disease

Sponsor: UCB Pharma

Conditions Crohn's Disease

Interventions Certolizumab Pegol Placebo

Updated 8 times since 2017 Last updated: Jul 14, 2020 Started: Mar 2, 2006 Primary completion: Nov 8, 2007 Completion: Nov 8, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00291668, this PHASE2 trial focuses on Crohn's Disease and remains completed. Sponsored by UCB Pharma, it has been updated 8 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Sep 2020 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB Pharma

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi-Gun, Japan , Asahikawa, Japan , Chikusino, Japan , Fukuoka, Japan , Kagoshima, Japan , Kashiwa, Japan , Kurashiki, Japan , Miyazaki-gun, Japan , Nagasaki, Japan , Nagoya, Japan and 12 more locations